|
41 Companies |
|
29 Products |
|
29 Products |
|
22 Mechanisms of Action |
|
2 Trials |
|
854 News |
|
| «12...56789101112131415...1617» |
- New P1 trial: Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP) (clinicaltrials.gov) - Mar 9, 2014
P1, N=27, Recruiting, Sponsor: Medicines for Malaria Venture
- chloroquine phosphate / Generic mfg.
Trial completion: Pharmacokinetic Study of Multi-dose Chloroquine (clinicaltrials.gov) - Mar 9, 2014
P4, N=30, Completed, Sponsor: Bandim Health Project
Recruiting --> Completed
- Enrollment open: A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria (clinicaltrials.gov) - Mar 5, 2014
P1/2, N=30, Recruiting, Sponsor: University of Oxford
Recruiting --> Completed Not yet recruiting --> Recruiting
- vivax malaria vaccine (ChAd63 PvDBP/MVA PvDBP) / University of Oxford
Enrollment closed: Phase Ia Study of ChAd63/MVA PvDBP (clinicaltrials.gov) - Mar 5, 2014
P1, N=24, Active, not recruiting, Sponsor: University of Oxford
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P1 trial: Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - Feb 24, 2014
P1, N=36, Recruiting, Sponsor: Infectious Disease Research Institute
- | chloroquine phosphate / Generic mfg., sulfadoxine/pyrimethamine / Generic mfg.
Trial completion: CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi (clinicaltrials.gov) - Feb 22, 2014
P4, N=210, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis (clinicaltrials.gov) - Feb 22, 2014
P1, N=45, Completed, Sponsor: Infectious Disease Research Institute
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Combination therapy: Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis (clinicaltrials.gov) - Feb 22, 2014
P1, N=48, Completed, Sponsor: Infectious Disease Research Institute
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| chloroquine phosphate / Generic mfg., azithromycin / Generic mfg., mefloquine / Generic mfg.
Trial completion: Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=238, Completed, Sponsor: Pfizer
No longer recruiting --> Completed No longer recruiting --> Completed
- Enrollment change: Antiretroviral Drug Interaction Study in Volunteers With HIV (clinicaltrials.gov) - Feb 20, 2014
P1, N=32, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
No longer recruiting --> Completed N=100 --> 32
- Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Enrollment closed: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Feb 20, 2014
P1/2, N=350, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 32 Recruiting --> Active, not recruiting
- Trial completion: Antiretroviral Drug Interaction Study in Volunteers With HIV (clinicaltrials.gov) - Feb 20, 2014
P1, N=32, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Trial completion, HEOR, Cost effectiveness: Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy (clinicaltrials.gov) - Feb 20, 2014
P3, N=3333, Completed, Sponsor: Gates Malaria Partnership
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=180, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Completed Recruiting --> Completed
- || Enrollment closed: Evaluation of CL Detect (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Trial completion: Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark) (clinicaltrials.gov) - Feb 9, 2014
P1, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Enrollment change: Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=532, Completed, Sponsor: Gen-Probe, Incorporated
Active, not recruiting --> Completed N=780 --> 532
- ||| Trial completion: Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=532, Completed, Sponsor: Gen-Probe, Incorporated
N=780 --> 532 Recruiting --> Completed
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi, Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
Trial initiation date, Combination therapy: Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger (clinicaltrials.gov) - Feb 3, 2014
P4, N=663, Recruiting, Sponsor: Epicentre
Recruiting --> Completed Initiation date: Dec 2012 --> Jun 2013
- Enrollment open: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=80, Recruiting, Sponsor: Drugs for Neglected Diseases
Initiation date: Dec 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi, Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
Enrollment open, Combination therapy: Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger (clinicaltrials.gov) - Feb 3, 2014
P4, N=663, Recruiting, Sponsor: Epicentre
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Enrollment closed, Combination therapy: QuinAct: Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria (clinicaltrials.gov) - Feb 1, 2014
P3, N=3600, Active, not recruiting, Sponsor: Universiteit Antwerpen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
New P4 trial, Combination therapy: Harmonized AS/MQ Efficacy Study - Thailand (clinicaltrials.gov) - Jan 30, 2014
P4, N=100, Recruiting, Sponsor: Armed Forces Research Institute of Medical Sciences, Thailand
- chloroquine phosphate / Generic mfg.
Enrollment closed: Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis (clinicaltrials.gov) - Jan 30, 2014
P1, N=30, Active, not recruiting, Sponsor: Sanaria Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion: Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults (clinicaltrials.gov) - Jan 30, 2014
P1, N=36, Completed, Sponsor: Sanaria Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial completion: MalaResT: Repellents as Added Control Measure to Long Lasting Insecticidal Nets (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=40000, Completed, Sponsor: Institute of Tropical Medicine, Belgium
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults (clinicaltrials.gov) - Jan 30, 2014
P1, N=30, Completed, Sponsor: Sanaria Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment open: Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays (clinicaltrials.gov) - Jan 28, 2014
P=N/A, N=2100, Recruiting, Sponsor: Gen-Probe, Incorporated
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- primaquine / Generic mfg.
Enrollment change: Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine (clinicaltrials.gov) - Jan 22, 2014
P4, N=1488, Completed, Sponsor: Indonesia University
Not yet recruiting --> Recruiting N=2403 --> 1488
- ||| Noxafil (posaconazole) / Merck (MSD)
Enrollment closed: STOP CHAGAS: A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (clinicaltrials.gov) - Jan 22, 2014
P2, N=160, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=2403 --> 1488 Recruiting --> Active, not recruiting
- primaquine / Generic mfg.
Trial completion: Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine (clinicaltrials.gov) - Jan 22, 2014
P4, N=1488, Completed, Sponsor: Indonesia University
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- New P1/2 trial: A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria (clinicaltrials.gov) - Jan 21, 2014
P1/2, N=30, Recruiting, Sponsor: University of Oxford
- levetiracetam / Generic mfg.
Enrollment open: A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM (clinicaltrials.gov) - Jan 15, 2014
P2, N=30, Recruiting, Sponsor: University of Rochester
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults (clinicaltrials.gov) - Jan 14, 2014
P1, N=30, Completed, Sponsor: Sanaria Inc.
Not yet recruiting --> Recruiting N=42 --> 30
- | Trial completion: Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults (clinicaltrials.gov) - Jan 14, 2014
P1, N=30, Completed, Sponsor: Sanaria Inc.
N=42 --> 30 Recruiting --> Completed
- Trial completion: Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso (clinicaltrials.gov) - Jan 14, 2014
P4, N=0, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Not yet recruiting --> Completed
- Trial initiation date: ChallengeIII: Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=16, Completed, Sponsor: Socrates Herrera Valencia
Not yet recruiting --> Completed Initiation date: Jun 2012 --> Oct 2012
- Trial completion: ChallengeIII: Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=16, Completed, Sponsor: Socrates Herrera Valencia
Initiation date: Jun 2012 --> Oct 2012 Not yet recruiting --> Completed
- Enrollment open: Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel (clinicaltrials.gov) - Jan 8, 2014
P1, N=66, Recruiting, Sponsor: Institut National de la Sant
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
Enrollment open: A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria (clinicaltrials.gov) - Jan 6, 2014
P2, N=300, Recruiting, Sponsor: sigma-tau i.f.r. S.p.A.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | chloroquine phosphate / Generic mfg., sulfadoxine/pyrimethamine / Generic mfg., azithromycin / Generic mfg.
Enrollment change: Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa (clinicaltrials.gov) - Jan 5, 2014
P3, N=2953, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=5044 --> 2953
- amphotericin b liposome / Generic mfg.
New P3 trial: Liposomal Amphotericin in Disseminated Leishmaniasis (clinicaltrials.gov) - Dec 30, 2013
P3, N=20, Completed, Sponsor: Hospital Universit
- amphotericin b liposome / Generic mfg.
Trial completion: Liposomal Amphotericin in Disseminated Leishmaniasis (clinicaltrials.gov) - Dec 29, 2013
P3, N=20, Completed, Sponsor: Hospital Universit
N=5044 --> 2953 Not yet recruiting --> Completed
- | pentoxifylline / Generic mfg.
Enrollment closed: Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis (clinicaltrials.gov) - Dec 25, 2013
P2/3, N=164, Active, not recruiting, Sponsor: Paulo Roberto Lima Machado
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- New P1 trial: Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel (clinicaltrials.gov) - Dec 16, 2013
P1, N=66, Recruiting, Sponsor: Institut National de la Sant
- | New P1 trial: Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults (clinicaltrials.gov) - Dec 15, 2013
P1, N=44, Recruiting, Sponsor: Fraunhofer, Center for Molecular Biotechnology
- Enrollment change: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Dec 12, 2013
P1/2, N=80, Recruiting, Sponsor: Drugs for Neglected Diseases
Recruiting --> Active, not recruiting N=202 --> 80
- || amphotericin b liposome / Generic mfg.
New P3 trial, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Dec 12, 2013
P3, N=132, Not yet recruiting, Sponsor: Drugs for Neglected Diseases
- | sodium valproate / Generic mfg.
New P4 trial: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Dec 11, 2013
P4, N=100, Enrolling by invitation, Sponsor: University of Pittsburgh
- Enrollment closed: LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine (clinicaltrials.gov) - Dec 11, 2013
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=202 --> 80 Recruiting --> Active, not recruiting